Editorial: Lurbinectedin for neuroendocrine tumors
A new editorial paper was published in Oncoscience, titled "Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer."
Oct 6, 2023
0
47
A new editorial paper was published in Oncoscience, titled "Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer."
Oct 6, 2023
0
47
Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented at the International Association ...
Sep 11, 2023
0
7
The Taiwan National Lung Cancer Early Detection Program detected 85% of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow ...
Sep 11, 2023
0
2
The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage ...
Sep 11, 2023
0
1
Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival ...
Sep 9, 2023
0
1
The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according ...
Sep 9, 2023
0
18
Fresh discoveries about a certain type of immune cell could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.
Aug 30, 2023
0
11
For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy, according ...
Aug 15, 2023
0
4
More than 14,000 cases of lung cancer were diagnosed in Australia in 2022. Survival rates are the worst of all cancers, with just 22% surviving five years after diagnosis.
Jul 31, 2023
0
1
While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in ...
Jul 13, 2023
0
16